Medicare

Medicare $ 62,264 $ 89,387 $ — $ 151,651 50.9 %

Medicare $ 60,550 $ 84,308 $ — $ 144,858 50.8 %

Because of this diversified portfolio, our blended payor mix was 48.4% Medicare, 13.1% Medicaid, 15.0% managed care and 23.5% private pay and other payment sources for the year ended December 31, 2025.

Medicare $ 41,830 $ 67,001 $ — $ 108,831 47.5 %

Medicare $ 39,625 $ 64,196 $ — $ 103,821 47.3 %

Medicare $ 39,676 $ 61,449 $ — $ 101,125 48.2 %

Medicare $ 127,891 $ 207,971 $ — $ 335,862 48.3 %

Medicare $ 32,403 $ 54,516 $ — $ 86,919 48.1 %

Medicare 44 % 45 %

Medicare 44 % 45 %

As of June 30, 2026 and December 31, 2025, the Company had $0.1 million in non-current deferred revenue, respectively, recorded within ‘Other long-term liabilities’ in the condensed balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.The Company’s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 United Healthcare 10 % 11 % 9 % 6 % Humana 10 % 8 % 10 % 4 % In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 35% and 34% of the Company’s total revenue for the three and six months ended June 30, 2026 compared to 33% and 35% for the three and six months ended June 30, 2025.

As of March 31, 2026 and December 31, 2025, the Company had $0.1 million in non-current deferred revenue, respectively, recorded within ‘Other long-term liabilities’ in the condensed balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.We collect reimbursement on behalf of customers covered by Medicare, which accounted for 32% of the Company’s total revenue for the three months ended March 31, 2026 compared to 36% for the three months ended March 31, 2025.

For the years ended December 31, 2025 and 2024, Medicare reimbursed 32% and 39%, respectively, of our total revenue to us.

As of September 30, 2025, the $3.0 million is recorded as a receivable in ‘Accounts receivable, net of allowance for credit losses’ and approximately $2.4 million remains in ‘Deferred revenue’ in the condensed balance sheet.The Company’s customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 United Healthcare 11 % 7 % 8 % 8 % In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 30% and 34% of the Company’s total revenue for the three and nine months ended September 30, 2025 compared to 40% for both the three and nine months ended September 30, 2024, respectively.The Company is subject to credit risk from its accounts receivable related to services provided to its customers.

Revenues from Medicare as a percentage of the Company's total revenue for the three months ended March 31, 2026 and 2025 were 35% and 41%, respectively.

Revenues from Medicare as a percentage of the Company's total revenue for the years ended December 31, 2025, 2024, and 2023 were 38%, 41%, and 44%, respectively.

Medicare $ 487,315 34.2 % $ 452,507 34.6 %

Medicare $ 489,636 34.5 % $ 443,476 34.7 %

A substantial portion of our revenue is generated from payments from third-party payors, including Medicare and Medicaid, which represent our largest sources of revenue and accounted for 33.7% and 40.5% of our routine revenue for the year ended December 31, 2025, respectively.

Revenue from the Medicare program amounted to 32.7% and 34.4% of the Company’s condensed consolidated net patient and resident revenue for the three months ended September 30, 2025 and 2024, respectively, and 34.0% and 34.5% of the Company’s condensed consolidated net patient and resident revenue for the nine months ended September 30, 2025 and 2024, respectively.

Revenue from the Medicare program amounted to 34.6% and 34.4% of the Company’s condensed consolidated net patient and resident revenue for the three months ended June 30, 2025 and 2024, respectively, and 34.6% and 34.5% of the Company’s condensed consolidated net patient and resident revenue for the six months ended June 30, 2025 and 2024, respectively.

Revenue from the Medicare program amounted to 34.7% and 34.6% of the Company’s condensed consolidated net patient and resident revenue for the three months ended March 31, 2025 and 2024, respectively.

Revenue from the Medicare program amounted to 34.4% and 32.8% of the Company’s condensed combined/consolidated net patient and resident revenue for the three months ended September 30, 2024 and 2023, respectively, and 34.5% and 40.6% of the Company’s condensed combined/consolidated net patient and resident revenue for the nine months ended September 30, 2024 and 2023, respectively.

Medicare 33 % 33 % 33 % 33 %

Medicare 34 % 33 %

Medicare Fee-For-Service accounted for 34%, 33% and 35% of our testing revenue.

Medicare 33 % 31 % 33 % 31 %

Medicare 33 % 31 % 31 %

For the three months ended June 30, 2026 and 2025, approximately 30% and 34%, respectively, of total revenue was derived from Medicare.

For the three months ended March 31, 2026 and 2025, approximately 27% and 37%, respectively, of total revenue was derived from Medicare.

For the years ended December 31, 2025, 2024 and 2023, approximately 34%, 38% and 40%, respectively, of total revenue was billed to Medicare.

For the three months ended September 30, 2025 and 2024, approximately 32% and 37%, respectively, of total revenue was derived from Medicare.

We derived 23.7% and 24.0% of our service revenue from the Medicare programs for the three and six months ended June 30, 2026, respectively, and 23.8% and 24.2% for the three and six months ended June 30, 2025, respectively.

We derived 24.3% and 24.7% of our service revenue from the Medicare programs for the three months ended March 31, 2026 and 2025, respectively.

We derived 23.7% and 24.9% of our service revenue from the Medicare programs for the years ended December 31, 2025 and 2024, respectively.

We derived 23.5% and 24.0% of our service revenue from the Medicare programs for the three and nine months ended September 30, 2025, respectively, and 24.5% and 25.3% for the three and nine months ended September 30, 2024, respectively.

We generate our skilled services revenue from Medicaid, Medicare, managed care, commercial insurance, and private pay.

For the three months ended June 30, 2026 and 2025, approximately 16.5% and 14.1%, respectively, of total revenue were paid by traditional Medicare on behalf of multiple customers.

For the three months ended March 31, 2026 and 2025, approximately 14.8% and 14.0%, respectively, of total revenue were paid by traditional Medicare on behalf of multiple customers.

For the years ended December 2025, 2024, and 2023, approximately 13.6%, 12.1%, and 12.8%, respectively, of total revenue were paid by Medicare on behalf of multiple customers.

For the three months ended September 30, 2025 and 2024, approximately 13.6% and 12.6%, respectively, of total revenue were paid by traditional Medicare on behalf of multiple customers.

Centers for Medicare and Medicaid Services 15 % 16 % 17 % 8 % 10 % 10 %

The following table presents revenue by payer type as a percentage of total revenue for the three and six-month periods ended July 4, 2026 and June 28, 2025, respectively: For the three-month periods ended For the six-month periods ended July 4, 2026 June 28, 2025 July 4, 2026 June 28, 2025 Medicaid MCO 59.4 % 58.6 % 59.4 % 58.6 % Medicaid 21.1 % 22.2 % 21.4 % 22.5 % Commercial 9.3 % 9.4 % 9.1 % 9.1 % Medicare 10.0 % 9.7 % 9.9 % 9.7 % Self-pay 0.2 % 0.1 % 0.2 % 0.1 % Total revenue 100.0 % 100.0 % 100.0 % 100.0 %

For the three-month periods ended April 4, 2026 March 29, 2025 Medicaid MCO 59.2 % 58.5 % Medicaid 21.8 % 22.8 % Commercial 8.9 % 8.8 % Medicare 9.9 % 9.8 % Self-pay 0.2 % 0.1 % Total revenue 100.0 % 100.0 %

The Company did not record any bad debt expense for the fiscal years ended January 3, 2026 or December 28, 2024.The following table presents revenue by payer type as a percentage of total revenue for the fiscal years ended January 3, 2026 and December 28, 2024: For the fiscal years ended January 3, 2026 December 28, 2024 Medicaid MCO 58.7 % 56.4 % Medicaid 22.8 % 23.5 % Commercial 8.5 % 9.6 % Medicare 9.9 % 10.4 % Self-pay 0.1 % 0.1 % Total revenue 100.0 % 100.0 %

The Company did not record any bad debt expense for the three and nine-month periods ended September 27, 2025 or September 28, 2024, respectively.The following table presents revenue by payer type as a percentage of total revenue for the three and nine-month periods ended September 27, 2025 and September 28, 2024, respectively: For the three-month periods ended For the nine-month periods ended September 27, 2025 September 28, 2024 September 27, 2025 September 28, 2024 Medicaid MCO 59.4 % 56.7 % 58.8 % 56.3 % Medicaid 23.3 % 25.0 % 22.8 % 23.4 % Commercial 7.4 % 7.9 % 8.5 % 9.7 % Medicare 9.7 % 10.3 % 9.7 % 10.5 % Self-pay 0.2 % 0.1 % 0.2 % 0.1 % Total revenue 100.0 % 100.0 % 100.0 % 100.0 %

Additionally, for the year ended December 31, 2025, Medicare represented 3% of total revenues.

Revenues received from Medicare represented approximately 13%, 12%, and 12% of total revenue for the years ended December 31, 2025, 2024, and 2023, respectively.

The federal Civil Monetary Penalties Law (the CMP Law), prohibits, among other things, (1) the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;

As of September 30, 2025, the Company has 18% of its accounts receivable with Medicare.